We are live on ! Find out more
SAGE

Sage Therapeutics
SAGE

Delisted

SAGE was delisted on the 30th of July, 2025.

Back to rankings

229 hedge funds and large institutions have $1.62B invested in Sage Therapeutics in 2020 Q1 according to their latest regulatory filings, with 50 funds opening new positions, 84 increasing their positions, 64 reducing their positions, and 84 closing their positions.

New
Increased
Maintained
Reduced
Closed

31% more repeat investments, than reductions

Existing positions increased: 84 | Existing positions reduced: 64

7% more call options, than puts

Call options by funds: $14.8M | Put options by funds: $13.8M

0.35% more ownership

Funds ownership: 108.08% → 108.42% (+0.35%)

14% less funds holding

Funds holding: 266 → 229 (-37)

40% less funds holding in top 10

Funds holding in top 10: 5 → 3 (-2)

40% less first-time investments, than exits

New positions opened: 50 | Existing positions closed: 84

60% less capital invested

Capital invested by funds: $4.04B → $1.62B (-$2.41B)

Holders
229
Holders Change
-37
Holders Change %
-13.91%
% of All Funds
5.05%
Holding in Top 10
3
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-40%
% of All Funds
0.07%
New
50
Increased
84
Reduced
64
Closed
84
Calls
$14.8M
Puts
$13.8M
Net Calls
+$1.01M
Net Calls Change
-$38.6M

Top Buyers

Rank Fund Capital Flow
1
Victory Capital Management
Victory Capital Management
Texas
+$82.1M
2
BC
Boxer Capital
California
+$68.5M
3
GPP
Great Point Partners
Connecticut
+$59.6M
4
ACA
Avoro Capital Advisors
New York
+$57.9M
5
Morgan Stanley
Morgan Stanley
New York
+$52.6M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$155M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$70.4M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$59.4M
4
TCM
TimesSquare Capital Management
New York
-$39.7M
5
American Century Companies
American Century Companies
Missouri
-$37.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
CFGS
301
Concourse Financial Group Securities
Alabama
– -$5.38K -93 Closed
PA
302
PSI Advisors
Florida
– -$6K -85 Closed
VAIA
303
Virtus Alternative Investment Advisers
Connecticut
– -$4K -59 Closed
HGWM
304
Harvest Group Wealth Management
Massachusetts
– -$2K -35 Closed
AA
305
Argent Advisors
Louisiana
– -$2K -33 Closed
MSFP
306
Mark Sheptoff Financial Planning
Connecticut
– -$2K -21 Closed
BAM
307
Bellevue Asset Management
Washington
– -$1K -13 Closed
VFA
308
Valeo Financial Advisors
Indiana
– -$1K -12 Closed
SFS
309
Sowell Financial Services
Arkansas
– -$1K -9 Closed
JCM
310
Jacobi Capital Management
Pennsylvania
– +$579 +10 New
9 10 11 12
13

SAGE Hedge Fund Activity: Q1 2020 in Review

229 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q1 2020, worth a combined $1.62B — down 60% from $4.04B a quarter earlier.

Sellers outnumbered buyers: 84 funds closed out of SAGE and 50 opened new positions — a net loss of 34 holders — while 64 trimmed existing stakes and 84 added.

The largest buyer was Victory Capital Management, adding an estimated $82.1M. The largest seller was T. Rowe Price Associates, cutting an estimated $155M.

  • 229 institutional investors held Sage Therapeutics (SAGE) as of Q1 2020, down from 266 in Q4 2019.
  • Funds reported $1.62B of Sage Therapeutics stock for Q1 2020, down 60% quarter-over-quarter.
  • 50 funds opened new Sage Therapeutics positions in Q1 2020 and 84 closed out, a net change of -34 holders.
  • The largest Sage Therapeutics buyer in Q1 2020 was Victory Capital Management, an estimated $82.1M added.
  • The largest Sage Therapeutics seller in Q1 2020 was T. Rowe Price Associates, an estimated $155M sold.

Based on aggregated 13F filings for Q1 2020.